Effect of the addition of sitagliptin and miglitol on insulin-treated type 2 diabetes

被引：11

作者：

Kishimoto M. ^{[1
]}

Noda M. ^{[1
]}

机构：

[1] Department of Diabetes and Metabolic Medicine, Center Hospital, and Diabetes and Metabolism Information Center, Diabetes Research Center, National Center for Global Health and Medicine, 1-21-1 Toyama Shinjuku-ku

来源：

Diabetes Therapy | 2012年 / 3卷 / 1期

关键词：

C-peptide; Continuous glucose monitoring; Glucagon-like peptide 1; Glucosedependent insulinotropic peptide; Insulin; Miglitol; Sitagliptin; Type; 2; diabetes;

D O I：

10.1007/s13300-012-0011-x

中图分类号：

学科分类号：

摘要：

Introduction: To examine the efficacy of sitagliptin and miglitol when added to ongoing insulin treatment in a patient with type 2 diabetes who had undergone partial gastrectomy. Methods: Continuous glucose monitoring (CGM) was performed and either sitagliptin or miglitol, or both, were added to fixed-dose insulin therapy. Blood was drawn at 0, 30, 60, and 120 min after breakfast, and C-peptide, glucagon, glucagon-like peptide (GLP)-1, and glucose-dependent insulinotropic peptide (GIP) were measured. Results: CGM showed that compared to insulin alone, the addition of either sitagliptin or miglitol, or both, to insulin achieved better glucose control. Compared to insulin alone, early postprandial increments in plasma C-peptide levels and suppressed glucagon levels were observed when sitagliptin was added. Glucagon suppression was even more prominent when both sitagliptin and miglitol were added. Compared to insulin alone, GLP-1 levels were higher during the early postprandial stage when sitagliptin or miglitol was added and even higher when both were added. GIP levels decreased when sitagliptin or miglitol, or both, were added to insulin therapy. Conclusion: The authors showed that the addition of sitagliptin or miglitol, or both, was effective in this insulin-treated patient with diabetes who had undergone gastrectomy. © The Author(s) 2012.

引用

页码：1 / 9

页数：8

共 29 条

[21]

Lee A., Patrick P., Wishart J., Horowitz M., Morley J.E., The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics, Diabetes Obes Metab., 4, pp. 329-335, (2002)

[22]

Narita T., Yokoyama H., Yamashita R., Et al., Comparison of the effects of 12-week administration of miglitol and voglibose on the responses of plasma incretins after a mixed meal in Japanese type 2 diabetic patients, Diabetes Obes Metab., 14, pp. 283-287, (2012)

[23]

Ahren B., Schweizer A., Dejager S., Et al., Vildagliptin enhances islet responsiveness to both hyper-and hypoglycemia in patients with type 2 diabetes, J Clin Endocrinol Metab., 94, pp. 1236-1243, (2009)

[24]

Kielgast U., Holst J.J., Madsbad S., Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual b-cell function, Diabetes., 60, pp. 1599-1607, (2011)

[25]

Creutsfeldt W.O.C., Kleine N., Willms B., Orskov C., Holst J.J., Nauck M.A., Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide 1 (7-36) amide in type 1 diabetic patients, Diabetes Care., 19, pp. 580-586, (1996)

[26]

Duppe J., Behme M.T., Hramiak I.M., McDonald T.J., Subcutaneous glucagon-like peptide 1 combine with insulin normalizes postcibal glycemic excursions in IDDM, Diabetes Care., 20, pp. 381-384, (1997)

[27]

Foley J.E., Ligueros-Saylan M., He Y.-L., Et al., Effect of vildagliptin on glucagon concentration during meals in patients with type 1 diabetes, Horm Metab Res., 40, pp. 727-730, (2008)

[28]

Rosenstock J., Rendell M., Gross J., Fleck P., Wilson C., Mekki Q., Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1c without increasing weight gain or hypoglycemia, Diabetes., 57, SUPPL. 1, (2008)

[29]

Fonseca V., Schweizer A., Albrecht D., Baron M.A., Chang I., Dejager S., Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes, Diabetologia., 50, pp. 1148-1155, (2007)

← 1 2 3 →